Mutant p53 and the Response to Chemotherapy and Radiation

Leila T. Tchelebi(Donald & Barbara Zucker School of Medicine at Hofstra/Northwell), Paul R. Graves(NewYork–Presbyterian Brooklyn Methodist Hospital), Hani Ashamalla(NewYork–Presbyterian Brooklyn Methodist Hospital)
Sub-cellular biochemistry/Subcellular biochemistry
January 1, 2014
10.1007/978-94-017-9211-0_8
Cited by 55

Related Papers

The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01
|Journal of Biological Chemistry|2000|541
Epidemiology of liver metastases
|Cancer Epidemiology|2020|274
Stroke among cancer patients
|Nature Communications|2019|211
Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer
|JAMA Oncology|2020|189
Trends in Cancer Incidence in US Adolescents and Young Adults, 1973-2015
|JAMA Network Open|2020|166